Although 2020 was a tough year for the biopharma industry — and most other industries as well — it appeared to rebound significantly in mid-2021. However, biotech stocks are generally getting hammered during 2022, although to be fair, the entire stock market is down.

GlaxoSmithKline exceeded expectations for the company’s first-quarter 2022 sales and earnings forecasts. This was largely driven by GSK’s sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and the company’s Shingrix vaccine against shingles.

Moderna Inc. said on February 18 the company is developing three new vaccines based on the same technology used for its COVID-19 shot, including one for viral infection shingles.

Britain’s GSK forecast growth in 2022 after racking up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, beating quarterly forecasts in the company’s first earnings report since rejecting Unilever’s bid for GlaxoSmithKline’s consumer arm.

Pfizer Inc. and Germany’s BioNTech SE will develop an mRNA-based vaccine for viral infection shingles, collaborating for the third time after the success of their COVID-19 vaccine based on the same technology.

GlaxoSmithKline said further growth from the company’s shingles vaccine – which has boosted earnings – would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.

GlaxoSmithKline beat second-quarter 2019 profit expectations with the help of strong demand for the company’s shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit for the full year than originally anticipated.

GlaxoSmithKline forecast 2019 sales of the company’s fast-growing shingles vaccine Shingrix to be “significantly” more than 1 billion pounds ($1.31 billion) as a drop in the British drugmaker’s free cash flow weighed on GSK’s shares.

GlaxoSmithKline is investing heavily in a Montana manufacturing facility that specializes in the manufacture of the company’s two-year-old shingles vaccine Shingrix, which is eying blockbuster status.

There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.